Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells

Blood

Volumn 101, Issue 10, 2003, Pages 4172-4179

  Link, Gabriela ^b   Ponka, Prem ^b   Konijn, Abraham M ^b   Breuer, William ^b   Cabantchik, Z Ioav ^b   Hershko, Chaim ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXY 1 NAPHTHALDEHYDE BENZOYLHYDRAZONE; 2 HYDROXY 1 NAPHTHALDEHYDE ISONICOTINOYLHYDRAZONE; DEFEROXAMINE; IRON; ISONIAZID DERIVATIVE; PYRIDOXAL BENZOYLHYDRAZONE; PYRIDOXAL ISONICOTINOYLHYDRAZONE; SALICYLALDEHYDE BENZOYLHYDRAZONE; SALICYLALDEHYDE ISONICOTINOYLHYDRAZONE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; FERRITIN; IRON CHELATING AGENT; ISONIAZID; PYRIDOXAL; PYRIDOXAL ISONICOTINOYL HYDRAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL LABELING; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; EXCRETION; FEMALE; FLUORESCENCE; HEART CELL CULTURE; HEART MUSCLE CELL; IN VITRO STUDY; IN VIVO STUDY; IRON CHELATION; IRON KINETICS; IRON STORAGE; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; RAT; TRANSFUSION; ANIMAL; BLOOD TRANSFUSION; CELL CULTURE; HEART; KINETICS; METABOLISM; NEWBORN; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; BLOOD TRANSFUSION; CELLS, CULTURED; DEFEROXAMINE; FEMALE; FERRITINS; HEART; IRON; IRON CHELATING AGENTS; IRON RADIOISOTOPES; ISONIAZID; KINETICS; PYRIDOXAL; RATS; RATS, WISTAR;

EID: 0038603210     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2382     Document Type: Article

References (45)

1. Gabutti V, Piga A. Results of long-term iron chelating therapy. Acta Haematol. 1996;95:26-36.
2. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival of medically treated patients with homozygous β thalassemia. N Engl J Med. 1994;331:574-578.
3. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheteters in high-risk β-thalassemia. Blood. 2000;95:1229-1236.
4. Hershko C, Konijn AM, Link G. Iron chelators for thalassaemia. Br J Haematol. 1998;101:399-406.
5. Modell B, Khan M, Darlison M. Survival in beta thalassaemia major in the United Kingdom: data from the U.K. Thalassaemia Register. Lancet. 2000;355:2051-2052.
6. Grady RW, Giardina PJ. Iron chelation: rationale for combination therapy. In: Badman DG, Bergeron RJ, Brittenham GM, eds. Iron Chelators, New Development Strategies. Ponte Vedra, FL: The Saratoga Group LLC; 2000:293-310.
7. Ponka P, Borova J, Neuwirth J, Fuchs O, Necas E. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim Biophys Acta. 1979;586:278-297.
8. Baker E, Vitolo mL, Webb JM. Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol. 1985;34:3011-3017.
9. Baker E, Richardson DR, Gross S, Ponka P. Evaluation of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology. 1992;15:492-501.
10. Hershko C. Biologic models for studying iron chelating drugs. Clin Haematol. 1989;2:293-321.
11. Link G, Pinson A, Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med. 1985;106:147-153.
12. Edward JT, Gauthier M, Chubb FL, Ponka P. Synthesis of new acylhydrazones as iron-chelating compounds. J Chem Eng Data. 1988;33:538-540.
13. Bjorklid E, Helgeland L. Sex difference in the ferritin content of rat liver. Biochim Biophys Acta. 1970;221:583-592.
14. Hershko C, Grady RW, Link G. Phenolic ethylenediamine derivatives: a study of orally effective iron chelators. J Lab Clin Med. 1984;103:337-346.
15. Hershko C, Cook JD, Finch CA. Storage iron kinetics, III: study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells. J Lab Clin Med. 1973;81:876-886.
16. Zevin S, Link G, Grady RW, Hider RC, Peter HH, Hershko C. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores. Blood. 1992;79:248-253.
17. Rivkin G, Link G, Simhon E, Cyjon RL, Klein JY, Hershko C. IRC11, a new synthetic chelator with selective interaction with catabolic red blood iron: evaluation in hypertransfused rats and in iron-loaded rat heart in culture. Blood. 1997;90:4180-4187.
18. Torrance JD, Bothwell TH. A simple technique for measuring storage iron concentrations in formalinized liver samples. S Afr J Med Sci. 1968;33:9-11.
19. Hershko C, Link G, Pinson A, Peter HH, Dobbin P, Hider RC. Iron mobilization from myocardial cells by 3-hydroxypyridin-4-one chelators: studies in rat heart cells in culture. Blood. 1991;77:2049-2053.
20. Link G, Pinson A, Hershko C. Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J Lab Clin Med. 1993;121:127-134.
21. Link G, Tirosh R, Pinson A, Hershko C. Role of iron in the potentiation of anthracycline cardiotoxicity: identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med. 1996;127:272-278.
22. Link G, Saada A, Pinson A, Konijn AM, Hershko C. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. J Lab Clin Med. 1998;131:466-474.
23. Link G, Konijn AM, Hershko C. Cardioprotective effect of alpha-tocopherol, ascorbate, deferoxamine, and deferiprone: mitochondrial function in cultured, iron-loaded heart cells. J Lab Clin Med. 1999;133:179-188.
24. Blondel B, Roijen I, Cheneval JP. Heart cells in culture: a simple method for increasing the proportion of myoblasts. Experientia. 1971;27:356-358.
25. Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI. The assessment of serum non-transferrin iron (NTBI) in chelation therapy and iron supplementation. Blood. 2000;95:2975-2982.
26. 50 of additive dose-response curves and application of these tabulated parameter values. J Pharmacol Toxicol Methods. 1995;33:137-145.
27. Dawson DA, Pöch G. A method for evaluating mechanistic aspects of chemical mixture toxicity. Toxicol Methods. 1997;7:267-278.
28. Holzmann S, Dittrich P, Pöch G. Dose-response curves of vasorelaxants: computerized calculation of combination effects using the example of nicorandil. J Clin Basic Cardiol. 1999;2:96-98.
29. Cohen AR, Galanello R, Piga A, DiPalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicenter study. Br J Haematol. 2000;108:305-312.
30. Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol. 2002;118:330-336.
31. Al-Refaie FN, Hershko C, Hoffbrand AV, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol. 1995;91:224-229.
32. Richardson DR, Ponka P. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease. J Lab Clin Med. 1998;131:306-314.
33. Cikrt M, Ponka P, Necas E, Neuwirt J. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br J Haematol. 1980;45:275-283.
34. Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel S. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal. J Lab Clin Med. 1981;98:99-107.
35. Brittenham GM. Pyridoxal isonicotinoyl hydrazone: an effective iron chelation after oral administration. Semin Hematol. 1990;27:112-116.
36. Vitolo LMW, Hefter GT, Clare BW, Webb J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class, part 2: formation constants with iron(III) and iron(II). Inorg Chim Acta. 1990;170:171-174.
37. Tsafack A, Loyevsky M, Ponka P, Cabantchik ZI. Mode of action of iron (III) chelators as antimalarials, IV: potentiation of desferal action by benzoyland isonicotinoyl-hydrazone derivatives. J Lab Clin Med. 1996;127:574-582.
38. Ponka P, Richardson D, Baker E, Schulmann HM, Edward JT. Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim Biophys Acta. 1988;967:122-129.
39. Liu ZD, Hider RC. Iron chelator chemistry. In: Templeton D, ed. Molecular and Cellular Iron Transport. New York, NY: Marcel Dekker; 2002:321-357.
40. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103:361-364.
41. Kayyali R, Hider RC, Porter JB. Combined chelation using deferiprone and deferoxamine induces synergistic inhibition of non-heme iron enzymes [abstract]. Blood. 2002;100:445.
42. Grady RW, Giardina PJ. Oral iron chelation: a potential role for HBED in combination therapy [abstract]. Blood. 1999;94:3293.
43. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A, a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001;97:1115-1122.
44. Piga A, Galanello R, Cappellini MD, et al. Phase II study of oral chelator ICL670 in thalassemia patients with transfusional iron overload: efficacy, safety, pharmacokinetics and pharmacodynamics after 6 months of therapy [abstract]. Blood. 2002;100:5.
45. Liu ZD, Liu DY, Hider RC. Synthesis, physico-chemical properties and biological evaluation of aromatic ester prodrugs of 1-(2′-hydroxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP102): orally active iron chelators with clinical potential. J Pharm Pharmacol. 1999;51:555-564.